VORONOI, a leading biotech in South Korea EGFR-Exon20Ins Lisenced out to ORIC Parmaceuticals in 2020 RET-Fusion Lisenced out to Inno.N in 2021 Anticipated upcoming IPO on KOSDAQ for 4Q, 2021
We're tracking Voronoi's market expansion
How Voronoi's international expansion compares to its competitors
VoronoiYouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 VoronoiYou | 0 | 0 | — | 0 | 0 |
Clinical Trial Manager
View postingWaltham, MA · Full-time · last mo.
임상시험 관리자(Clinical Trial Manager)
View postingIncheon, South Korea · 2mo ago
Artificial Intelligence Researcher for Chemical Reaction Automation
View postingIncheon, South Korea · 11mo ago
No active campaigns
Sign up to track this company and get alerted the moment something changes.
D&D Pharmatech, Alteogen, and Peptron stocks surged as D&D prepares to present MASH pipeline data at EASL conference. Analysts highlight upcoming clinical results and technology transfer deals.
KOSDAQ index fell 0.58% to 1174.31 as foreigners and institutions sold. Ecopro dropped 4.32%, while Ligachem Biosciences surged 7.01% and Caregen jumped 14.11%.
KOSDAQ biotech stocks plunged mid-session despite upcoming ASCO conference. Rising interest rates reduced market interest in biotech sector. Analysts suggest ASCO may reveal cancer drug trends.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about Voronoi's business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
